🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We a16z are thrilled to announce our Series A investment in Valar Labs, which is building AI tools to assist oncologists in cancer treatment decisions. There are roughly 2 million new cancer diagnoses annually in the US alone. Each diagnosis involves a biopsy of the patient's

Leveraging AI biomarkers to navigate the evolving landscape of #BladderCancer treatment Stephen B. Williams, MD, MBA, MS, FACHE UTMBUrology joins Zach Klaassen Georgia Cancer Center to discuss this innovative AI biomarker for #NMIBC > bit.ly/44JLkLj Valar Labs

It's been a privilege to collaborate with yair lotan Ashish M. Kamat, MD, MBBS on our international 12 center clinical validation study predicting outcomes and response to BCG using #CHAI biomarkers. We are excited for the impact #Vesta will have for bladder cancer patient care. UroToday.com

30 Under 30 Healthcare 2025: Advancing AI, Delivering Care And Creating New Therapies #ForbesUnder30 trib.al/o7L5YAz

These entrepreneurs and researchers are taking on some of healthcare’s biggest challenges, from developing new drugs to building new devices to expanding access to care. #ForbesUnder30 trib.al/BUIVaEE

AI Powered Model to Predict Response to Intravesical BCG Versus Gem-Doce for HR NMIBC Vignesh Packiam, MD Valar Labs UroToday.com #SUO24 🎯 CHAI biomarker +ve: Predictive of ⬆️ HG-RFS in pts treated with Gem-Doce vs BCG ⚡️First AI-based histologic biomarker to predict clinical

An #ArtificialIntelligence-powered predictive biomarker for response to intravesical BCG versus gemcitabine-docetaxel for high-grade #NMIBC. Presentation by Vignesh Packiam, MD Rutgers Cancer Institute. #AUA25 written coverage by Rashid K. Sayyid USC > bit.ly/4jQSrbg Amer. Urol. Assn.

Excited to share this paper which has been many years in the making! This is the first publication of a predictive (AI-histology based) biomarker to guide rational use of BCG vs Gem/Doce for newly diagnosed HG NMIBC pubmed.ncbi.nlm.nih.gov/40287344/ Curves say it all 👇🏾

🌟AI meets #BladderCancer care! This new study explores the CHAI biomarker, an AI-powered histologic tool that: 🔸️Predicts poor responders to BCG 🔸️ Is not associated with poor outcomes on Gemcitabine/Docetaxel 🔸️May help personalize therapy in high-grade NMIBC A step

Our recent publication in European Urology Oncology demonstrates - for the first time -that an AI-powered histologic biomarker (CHAI) can predict response to intravesical BCG vs. gemcitabine/docetaxel in high-grade NMIBC. A critical step forward in precision intravesical therapy.

Comprehensive breakdown of our recent European Urology Oncology publication

Excited to share our Valar Labs publication in European Urology validating Vesta Risk Stratify computational histology AI biomarkers to predict recurrence and progression in High Grade Ta Bladder Cancer. (1/5) Publication: authors.elsevier.com/c/1lFoD14kpm0h…